Drug Trial Radar · NCT01840605
A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
303
Actual
Start
Mar 2013
Primary completion
Nov 2013
Study completion Nov 2013
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Apr 26, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 7 years, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to verify the non-inferiority of TAU-284 to ketotifen fumarate dry syrup in the change in the severity of pruritus after the treatment period.
Conditions
- Dermatitis
- Atopic
Interventions
Bepotastine besilateDrug
Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day
ketotifen fumarateDrug
Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Pruritus ScoreTime frame: Baseline and 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical Corporation Kojinkai Asanuma Dermatology Clinic
Hokkaido, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.